Anaphore cultures $25M for protein treatments
Biotech firm Anaphore has raised $25 million in first-round funding to continue development of protein therapies for cancer and immune diseases. The money, which includes $8 million in seed financing received in March, is enough to push a couple of its drugs into clinical trials.
In particular, Anaphore works to create artimers — treatments manufactured from naturally secreted human serum protein. The La Jolla, Calif.-based company says they are more efficient to produce and easier to commercialize than treatments that have been used in the past — namely, antibodies.
Apposite Capital, Versant Ventures and 5AM Ventures shared the lead in the round.
Next Story: CES: Samsung dives into connected TV market
Previous Story: Anacor takes $50M to treat fungal infections
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.